These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9890518)

  • 21. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 23. Genetic stability and product consistency of rDNA derived biologicals.
    Lambert KJ
    Biologicals; 1993 Jun; 21(2):151. PubMed ID: 8297596
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic stability and recombinant product consistency.
    Burstyn D; Copmann T; Dinowitz M; Garnick R; Losikoff A; Lubiniecki A; Wiebe M
    Biologicals; 1993 Jun; 21(2):147-9. PubMed ID: 8297595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology: nucleic acid characterization and genetic stability.
    Biologicals; 1993 Mar; 21(1):81-3. PubMed ID: 8217122
    [No Abstract]   [Full Text] [Related]  

  • 26. Quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():223-34. PubMed ID: 9737399
    [No Abstract]   [Full Text] [Related]  

  • 27. Quality of biotechnological products: stability testing of biotechnological/biological products. Annex to the ICH Harmonised Tripartite Guideline for the Stability Testing of New Drug Substances and Products.
    Dev Biol Stand; 1998; 93():211-9. PubMed ID: 9737398
    [No Abstract]   [Full Text] [Related]  

  • 28. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical use of biologicals produced in continuous cell lines.
    Hoffman T; Fratantoni J; Murano G
    Dev Biol Stand; 1989; 70():211-4. PubMed ID: 2668073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-process testing and limits.
    Sjöholm I
    Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685
    [No Abstract]   [Full Text] [Related]  

  • 32. Process validation.
    Beatrice MG
    Dev Biol Stand; 1998; 96():169-71; discussion 177-9. PubMed ID: 9890529
    [No Abstract]   [Full Text] [Related]  

  • 33. Status of WHO concerning continuous cell lines as substrates for the production of biologicals.
    Grachev V; Magrath D
    Dev Biol Stand; 1989; 70():215-9. PubMed ID: 2759349
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 36. Genetic stability and product consistency of rDNA-derived biologicals from mammalian cells.
    Bebbington CR; Lambert K
    Dev Biol Stand; 1994; 83():183-4. PubMed ID: 7883094
    [No Abstract]   [Full Text] [Related]  

  • 37. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung.
    Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE
    Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a statistical strategy to evaluate sources of variability in viral safety experiments for a recombinant biopharmaceutical.
    McAllister PR; Shadle PJ; Smith TM; Scott RG; Lubiniecki AS
    Dev Biol Stand; 1996; 88():111-21. PubMed ID: 9119122
    [No Abstract]   [Full Text] [Related]  

  • 39. Notes to applicants for marketing authorizations on the production and quality control of medicinal products derived by recombinant DNA technology. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
    J Biol Stand; 1989 Jul; 17(3):223-31. PubMed ID: 2793874
    [No Abstract]   [Full Text] [Related]  

  • 40. Micro biochemical engineering to accelerate the design of industrial-scale downstream processes for biopharmaceutical proteins.
    Titchener-Hooker NJ; Dunnill P; Hoare M
    Biotechnol Bioeng; 2008 Jun; 100(3):473-87. PubMed ID: 18438873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.